BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-4.07%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.61B
AUM Growth
+$8.61B
(-11%)
Cap. Flow
-$378M
Cap. Flow
% of AUM
-4.39%
Top 10 Holdings %
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30
Top Buys
| 1 |
Outset Medical
OM
|
$66.1M |
| 2 |
Boston Scientific
BSX
|
$42.1M |
| 3 |
CareDx
CDNA
|
$31.2M |
| 4 |
Pacific Biosciences
PACB
|
$30.3M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$29.8M |
Top Sells
| 1 |
Biogen
BIIB
|
$106M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$81.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
$75.3M |
| 4 |
Danaher
DHR
|
$68.9M |
| 5 |
Humana
HUM
|
$68M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Industrials | 0.69% |
| 3 | Energy | 0.03% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Privia Health
PRVA
$2.84B
| $14M | 0.16% |
525,000
| – | – |
|
102
Guardant Health
GH
$8.11B
| $13.9M | 0.16% |
209,712
-83,900
| -29% | -$5.56M |
|
103
Amgen
AMGN
$153B
| $13M | 0.15% |
53,800
-4,350
| -7% | -$1.05M |
|
104
Health Catalyst
HCAT
$228M
| $11.1M | 0.13% |
424,611
-268,055
| -39% | -$7M |
|
105
Procept Biorobotics
PRCT
$2.11B
| $10M | 0.12% |
286,075
+112,426
| +65% | +$3.93M |
|
|
ONEM
106
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $9.27M | 0.11% |
836,190
| – | – |
|
107
Wave Life Sciences
WVE
$1.27B
| $9.13M | 0.11% |
4,562,858
-40,000
| -0.9% | -$80K |
|
108
Black Diamond Therapeutics
BDTX
$164M
| $9.12M | 0.11% |
3,293,000
-170,000
| -5% | -$471K |
|
109
Dentsply Sirona
XRAY
$2.77B
| $7.83M | 0.09% |
159,129
| – | – |
|
110
American Well
AMWL
$112M
| $7.45M | 0.09% |
88,485
-17,907
| -17% | -$1.51M |
|
|
SGEN
111
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.26M | 0.08% |
50,400
+4,400
| +10% | +$634K |
|
112
Harmony Biosciences
HRMY
$2.16B
| $6.08M | 0.07% |
124,961
+3,800
| +3% | +$185K |
|
113
AstraZeneca
AZN
$255B
| $5.94M | 0.07% |
89,600
+30,600
| +52% | +$2.03M |
|
114
BioMarin Pharmaceuticals
BMRN
$11.3B
| $5.75M | 0.07% |
74,600
+3,200
| +4% | +$247K |
|
115
Q32 Bio
QTTB
$20.9M
| $5.01M | 0.06% |
91,507
-5,000
| -5% | -$274K |
|
116
Gilead Sciences
GILD
$140B
| $4.96M | 0.06% |
83,450
-73,550
| -47% | -$4.37M |
|
117
Johnson & Johnson
JNJ
$429B
| $4.91M | 0.06% |
27,700
+7,500
| +37% | +$1.33M |
|
|
118
Biogen
BIIB
$20.8B
| $4.71M | 0.05% |
22,350
-502,650
| -96% | -$106M |
|
|
BHVN
119
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.65M | 0.05% |
39,207
+1,200
| +3% | +$142K |
|
120
Pulmonx
LUNG
$67.6M
| $4.38M | 0.05% |
176,510
| – | – |
|
121
Doximity
DOCS
$12.6B
| $4.32M | 0.05% |
+82,860
| New | +$4.32M |
|
122
Neuropace
NPCE
$310M
| $4.17M | 0.05% |
507,930
| – | – |
|
|
OLK
123
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $4.16M | 0.05% |
235,273
| – | – |
|
|
BNR
124
Burning Rock Biotech
BNR
$85.6M
| $4.08M | 0.05% |
43,887
-5,102
| -10% | -$474K |
|
125
Arcus Biosciences
RCUS
$1.24B
| $3.53M | 0.04% |
111,700
+24,200
| +28% | +$764K |
|